Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Biosciences, Inc.

https://www.neurocrine.com/

Latest From Neurocrine Biosciences, Inc.

Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise

Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.

Clinical Trials Research & Development

India Q2 Preview: Glenmark, Cipla Emerge Stronger

With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.

Commercial Coronavirus COVID-19

Early Promise From Axovant’s Parkinson’s Gene Therapy

Gene therapy shows promise in treating movement disorders in 4 patients, matching longer-term results from rivals Neurocrine Biosciences and Voyager Therapeutics.

Commercial Clinical Trials

Finance Watch: Two New VC Funds Raise $755m To Fund Innovation

Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register